Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...